Status:
ACTIVE_NOT_RECRUITING
Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)
Lead Sponsor:
Mayo Clinic
Conditions:
Non-muscle Invasive Bladder Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to evaluate patient-reported preference for urine based molecular testing (CxBladder Monitor) compared to cystoscopy for patients on surveillance for Nonmuscle Invasive Bl...
Eligibility Criteria
Inclusion
- Male or female with a history of histologically confirmed nonmuscle invasive bladder cancer (NMIBC) who have at least 6 months of disease-free survival from last recurrence.
- Able to provide urine for testing and comply with study protocol.
- Have an email address and be willing to complete surveys online.
Exclusion
- History of non-urothelial bladder cancer (primary squamous, adenocarcinoma, and small cell carcinoma)
- Patients with predominant (\>50%) variant histology
- Patients with a history of upper tract and/or urethral cancer
- Women who are pregnant
Key Trial Info
Start Date :
November 16 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2025
Estimated Enrollment :
107 Patients enrolled
Trial Details
Trial ID
NCT06126796
Start Date
November 16 2023
End Date
November 1 2025
Last Update
June 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Arizona
Scottsdale, Arizona, United States, 85259